WO2023136785A1 - Noscapine extraction from poppy (opium) capsules - Google Patents
Noscapine extraction from poppy (opium) capsules Download PDFInfo
- Publication number
- WO2023136785A1 WO2023136785A1 PCT/TR2022/050028 TR2022050028W WO2023136785A1 WO 2023136785 A1 WO2023136785 A1 WO 2023136785A1 TR 2022050028 W TR2022050028 W TR 2022050028W WO 2023136785 A1 WO2023136785 A1 WO 2023136785A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- noscapine
- solution
- hours
- minimum
- maximum
- Prior art date
Links
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 title claims abstract description 45
- 229960004708 noscapine Drugs 0.000 title claims abstract description 45
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 title claims abstract description 43
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 238000000605 extraction Methods 0.000 title claims abstract description 25
- 239000002775 capsule Substances 0.000 title claims abstract description 19
- 239000008896 Opium Substances 0.000 title claims abstract description 17
- 229960001027 opium Drugs 0.000 title claims abstract description 17
- 240000001090 Papaver somniferum Species 0.000 title description 9
- 235000008753 Papaver somniferum Nutrition 0.000 title description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 37
- 239000000243 solution Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 4
- 238000005119 centrifugation Methods 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 238000005303 weighing Methods 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 14
- 239000012535 impurity Substances 0.000 description 7
- 229960005181 morphine Drugs 0.000 description 7
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 229960004126 codeine Drugs 0.000 description 3
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 150000007975 iminium salts Chemical class 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 239000010902 straw Substances 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 229930194309 Papaverrubine Natural products 0.000 description 1
- XXNNKVDBGXCFHP-GGPKGHCWSA-N Papaverrubine E Natural products N([C@H]1[C@@H](C2=C3)O[C@@H](C4=C5OCOC5=CC=C41)OC)CCC2=CC1=C3OCO1 XXNNKVDBGXCFHP-GGPKGHCWSA-N 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 235000006502 papoula Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0261—Solvent extraction of solids comprising vibrating mechanisms, e.g. mechanical, acoustical
- B01D11/0265—Applying ultrasound
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/0004—Crystallisation cooling by heat exchange
- B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange
Definitions
- the invention relates to a standardized extraction method for obtaining noscapine from opium capsules.
- Papaver somniferum plant contains many alkaloids. While more oil is obtained from its seeds, its capsules contain alkaloids such as morphine, codeine, papaverine and noscapine. However, depending on the properties of the capsule, some capsules contain codeine, some capsules contain morphine, and some capsules contain noscapine. Generally, morphine and codeine are extracted from capsules, although noscapine is a non-narcotic alkaloid that is produced industrially on a limited scale. With the COVID-19 pandemic, there is a global demand for noscapine, the main indication of which is cough relief.
- Noscapine (Chemical Formula 1) is a natural product found in opium, which can cross the blood-brain barrier and shows its effect on the central nervous system and suppresses cough. It is known to be used in cough suppressants in Japan and the Asian continent. Additionally, noscapine has been shown to reduce tumor growth in animal studies.
- Noscapine is extracted from crude opium.
- raw opium may contain other substances such as morphine.
- Morphine is a controlled substance that is subject to government control in many places, the amount of crude opium available to a noscapine manufacturer may be limited by the amount of morphine in the raw opium.
- noscapine manufacturers have turned to a blend of stems and capsules derived from the harvested opium poppy (Papaver somniferum) as an alternative source of noscapine.
- the poppy straw may have a much higher noscapine content than the morphine content.
- the poppy stem and pod may also contain a number of impurities such as papaverrubin compounds.
- Papaverrubine compounds can be irreversibly converted to red iminium salts under acidic conditions.
- red iminium salts when present, impart an undesirable reddish color to the noscapine product.
- US8394814 has provided a method for obtaining noscapine from an opium source containing at least one impurity that undergoes an irreversible color change when exposed to a pH of less than about 5.
- noscapine is soluble in a first solvent such as acetone, acetonitrile, which has a pH greater than about 5.
- a first solvent such as acetone, acetonitrile, which has a pH greater than about 5.
- noscapine is recrystallized, separating it from the impurity causing the color change.
- US4029797 relates to the preparation of a cough syrup that masks the characteristic unpleasant taste of noscapine.
- the invention relates to the production of noscapine from opium capsules or opium capsules with stems.
- the process steps are given below. a) Opium capsules are weighed, b) It is passed through a 0, 1-5 mm sieve , it is converted micronized powder as much as possible, as a critical aspect of invention, c) As a pre-treatment before extraction, it is mixed with a high-speed ultrasonic or nonultrasonic mixer for 15 to 75 minutes, pH: 9.5 is adjusted with NaOH 1% solution, d) For each kg of the mass consisting of capsules rich in Noscapin, a solvent system containing Ethanol 80% and distilled water 20%between 4 and 8 liters, brought to a temperature of minimum 40°C and maximum 70°C, is added, preferably the temperature is 50-55°C, e) Extraction is carried out in the period of 1 hour to 6 hours, preferably the extraction time is 2 hours, f) After the ethanol is evaporated in the extraction system, the
- noscapine obtained is 99% to 101% pure, and noscapine is obtained with a total impurity of less than 0.50% and each impurity less than 0.2%, in accordance with the limits of the noscapine monograph available in the European Pharmacopoeia.
Landscapes
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Acoustics & Sound (AREA)
- Thermal Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a standardized extraction method for obtaining noscapine from opium capsules.
Description
NOSCAPINE EXTRACTION FROM POPPY (OPIUM) CAPSULES
Technical Area
The invention relates to a standardized extraction method for obtaining noscapine from opium capsules.
Background of the Invention
Papaver somniferum plant contains many alkaloids. While more oil is obtained from its seeds, its capsules contain alkaloids such as morphine, codeine, papaverine and noscapine. However, depending on the properties of the capsule, some capsules contain codeine, some capsules contain morphine, and some capsules contain noscapine. Generally, morphine and codeine are extracted from capsules, although noscapine is a non-narcotic alkaloid that is produced industrially on a limited scale. With the COVID-19 pandemic, there is a global demand for noscapine, the main indication of which is cough relief.
Chemical Formula 1
Noscapine (Chemical Formula 1) is a natural product found in opium, which can cross the blood-brain barrier and shows its effect on the central nervous system and suppresses cough. It is known to be used in cough suppressants in Japan and the Asian continent. Additionally, noscapine has been shown to reduce tumor growth in animal studies.
Noscapine is extracted from crude opium. In addition, raw opium may contain other substances such as morphine. Morphine is a controlled substance that is subject to government control in many places, the amount of crude opium available to a noscapine manufacturer may be limited by the amount of morphine in the raw opium.
Because of this limitation, noscapine manufacturers have turned to a blend of stems and capsules derived from the harvested opium poppy (Papaver somniferum) as an alternative source of noscapine. Depending on the particular type of poppy and the post-harvest processing of the poppy straw, the poppy straw may have a much higher noscapine content than the morphine content.
However, the poppy stem and pod may also contain a number of impurities such as papaverrubin compounds. Papaverrubine compounds can be irreversibly converted to red iminium salts under acidic conditions. In purified noscapine products, red iminium salts, when present, impart an undesirable reddish color to the noscapine product. There is a need to develop
a method for separating noscapine from an opium source that may contain papaverrubins or other impurities that undergo irreversible color changes when exposed to acidic processing conditions.
As a solution to this problem, US8394814 has provided a method for obtaining noscapine from an opium source containing at least one impurity that undergoes an irreversible color change when exposed to a pH of less than about 5. According to the method, noscapine is soluble in a first solvent such as acetone, acetonitrile, which has a pH greater than about 5. By adding water as a second solvent to the reaction mixture, noscapine is recrystallized, separating it from the impurity causing the color change.
US4029797 relates to the preparation of a cough syrup that masks the characteristic unpleasant taste of noscapine.
Description of the Invention
Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
In the case of conflict, the present specification, including definitions, will control. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.
Reference throughout this specification to "one aspect", "an aspect", "another aspect", "a particular aspect", "combinations thereof" means that a particular feature, structure or characteristic described in connection with the invention aspect is included in at least one aspect of the present invention. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same aspect. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more aspects.
The term "comprise(s)", or "comprising" is generally used in the sense of include(s)/including, that is to say, permitting the presence of one or more features or components. The terms "comprise(s)" and "comprising" also encompass the more restricted ones "consist(s)" and "consisting", respectively.
As used in the specification and claims, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise.
The invention relates to the production of noscapine from opium capsules or opium capsules with stems. The process steps are given below. a) Opium capsules are weighed,
b) It is passed through a 0, 1-5 mm sieve , it is converted micronized powder as much as possible, as a critical aspect of invention, c) As a pre-treatment before extraction, it is mixed with a high-speed ultrasonic or nonultrasonic mixer for 15 to 75 minutes, pH: 9.5 is adjusted with NaOH 1% solution, d) For each kg of the mass consisting of capsules rich in Noscapin, a solvent system containing Ethanol 80% and distilled water 20%between 4 and 8 liters, brought to a temperature of minimum 40°C and maximum 70°C, is added, preferably the temperature is 50-55°C, e) Extraction is carried out in the period of 1 hour to 6 hours, preferably the extraction time is 2 hours, f) After the ethanol is evaporated in the extraction system, the remaining aqueous phase is brought to a temperature between 40° C and 50° C before being filtered, filtered with the help of cellulose-containing or cartridge filters, g) Acetonitrile is added into the obtained aqueous solution (Acetonitrile comprising solvent system as acetonitrile 80%and distilled water 20%) and the extraction is carried out at a temperature of 50°C to 70°C, preferably at 50-55°C for a minimum of 1 hour and a maximum of 3 hours, h) After the extraction process, a sufficient amount of minimum 0.01%, maximum 1% activated carbon is added to the extraction system by mixing, i) Acetonitrile solution with activated carbon is taken into a separate glass or steel reactor for crystallization after filtration, j) Temperature of Acetonitrile 80% Water 20% extraction solvent is increased to 50° C, distilled water is added to the system within a minimum of 1 hour and a maximum of 24 hours, and concentration rate of extraction solvent system is changed to Acetonitril %20 and Water 80% concentration. Simultaneously in a minimum of 1 hour and a maximum of 24 hours, temperature of the extraction solvent system is decreased to minimum 2° C maximum 15 ° C with the help of a cooling system (with the help of chillers or cooled glass reactors), after 12 hours or 24 hours, the precipitated solution is filtered at a temperature not exceeding 8 ° C to obtain raw noscapine, k) The filtered acetonitrile- water solution is centrifuged at minimum 1000 G and maximum 5000 G by industrial centrifuge, precipitated noscapine is added to the crude noscapine crystals precipitated in the previous step, l) Raw noscapine is dried in an oven or industrial powder dryers with a moisture content of around 0.1% or 0.5%, m) The dried raw noscapine which looks slightly yellow to greenish color is washed with acetone solution or methanol solution in order to reduce the amount of impurity thanks to the washing process, another aspect of invention n) Noscapin obtained after washing is dried at 30° C (minimum) , 80° C (maximum) so that the moisture content is adjusted to the pharmacopoeial limits. The pharmacopoeial noscapine obtained is 99% to 101% pure, and noscapine is obtained with a total impurity of less than 0.50% and each impurity less than 0.2%, in accordance with the limits of the noscapine monograph available in the European Pharmacopoeia.
Claims
1. A process for obtaining noscapine from opium capsules or a mixture of stem and capsule, comprising the steps of; a) Weighing the opium capsules, sifting them with a 0,1-5 mm sieve, turning them into micronized powder as much as possible, b) Mixing for 15 to 75 minutes with a high-speed ultrasonic or non-ultrasonic mixer as a pretreatment before extraction, adjusting to pH: 9.5 with NaOH 1% solution, c) The addition of a solvent system containing Ethanol 80% and distilled 20% water between 4 and 8 liters per kg of mass, brought to a temperature of minimum 40°C and maximum 70°C, preferably 50-55°C, d) Extracting for 1 hour to 6 hours, preferably 2 hours, e) After the ethanol is evaporated in the extraction system, the remaining aqueous phase is brought to a temperature between 40° C and 50° C before filtering, filtered with the help of cellulose-containing or cartridge filters, f) Adding 80% acetonitrile to the obtained aqueous solution, containing 20% distilled water, and extraction between 50°C and 70°C, preferably at 50-55°C for a minimum of 1 hour and a maximum of 3 hours, g) Adding a sufficient amount of minimum 0.01%, maximum 1% activated carbon to the extraction system after the extraction process, h) Transfer the acetonitrile solution with activated carbon into a separate glass or steel reactor for the crystallization process after filtration, i) Heating the solution to 50°C, adding distilled water to the system within a minimum of 1 hour and a maximum of 24 hours, bringing 20% acetonitrile to 80% water concentration, simultaneously cooling the solution system to 2-15°C within a minimum of 1 hour and a maximum of 24 hours, filtering the crude noscapine solution, which precipitated after 12 hours or 24 hours, at a temperature not exceeding 8°C, j) Centrifugation of the filtered acetonitrile-water solution at a minimum of 1000 G and a maximum of 5000 G, adding the precipitated noscapine to the crude noscapine crystals precipitated in the previous step, k) Drying the raw noscapine moisture content of 0.1% to 0.5% in an oven or industrial powder dryers, l) Washing the dried raw noscapine with acetone solution or methanol solution, m) Drying between 30° C- 80° C.
2. A process for obtaining noscapine according to claim 1, comprising the steps of; a) Weighing the opium capsules, sifting them with a 0,1-5 mm sieve, turning them into micronized powder as much as possible, b) Mixing for 15 to 75 minutes with a high-speed ultrasonic or non-ultrasonic mixer as a pretreatment before extraction, adjusting to pH: 9.5 with NaOH 1% solution, c) The addition of a solvent system containing Ethanol 80% and distilled water 20% between
4 and 8 liters per kg of mass, brought to a minimum temperature of 50-55°C, d) 2 hours of extraction, e) After the ethanol is evaporated in the extraction system, the remaining aqueous phase is brought to a temperature between 40° C and 50° C before filtering, filtered with the help of cellulose-containing or cartridge filters, f) Adding 80% acetonitrile to the obtained aqueous solution containing 20% distilled water, extraction at 50-55°C for a minimum of 1 hour and a maximum of 3 hours, g) Adding a sufficient amount of minimum 0.01%, maximum 1% activated carbon to the extraction system after the extraction process,
4
h) Transfer the acetonitrile/water solution with activated carbon into a separate glass or steel reactor for the crystallization process after filtration, i) Heating the solution to 50°C, adding distilled water to the system within a minimum of 1 hour and a maximum of 24 hours, bringing 20% acetonitrile to 80% water concentration, simultaneously cooling the solution system to 2-15°C within a minimum of 1 hour and a maximum of 24 hours, Filtering the crude noscapine solution, which precipitated after 12 hours or 24 hours, at a temperature not exceeding 8°C, j) Centrifugation of the filtered acetonitrile-water solution at a minimum of 1000 G and a maximum of 5000 G, adding the precipitated noscapine to the crude noscapine crystals precipitated in the previous step, k) Drying the raw noscapine moisture content of 0.1% to 0.5% in an oven or industrial powder dryers, l) Washing the dried raw noscapine with acetone solution or methanol solution, m) Drying between 30° C- 80° C.
5
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2022/050028 WO2023136785A1 (en) | 2022-01-17 | 2022-01-17 | Noscapine extraction from poppy (opium) capsules |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TR2022/050028 WO2023136785A1 (en) | 2022-01-17 | 2022-01-17 | Noscapine extraction from poppy (opium) capsules |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023136785A1 true WO2023136785A1 (en) | 2023-07-20 |
Family
ID=87279509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2022/050028 WO2023136785A1 (en) | 2022-01-17 | 2022-01-17 | Noscapine extraction from poppy (opium) capsules |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023136785A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010039218A1 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Method of purifying crude noscapine |
WO2016053678A1 (en) * | 2014-09-30 | 2016-04-07 | Noramco, Inc. | Method for extraction and concentration of alkaloids using dimethyl ether |
-
2022
- 2022-01-17 WO PCT/TR2022/050028 patent/WO2023136785A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010039218A1 (en) * | 2008-09-30 | 2010-04-08 | Mallinckrodt Inc. | Method of purifying crude noscapine |
WO2016053678A1 (en) * | 2014-09-30 | 2016-04-07 | Noramco, Inc. | Method for extraction and concentration of alkaloids using dimethyl ether |
Non-Patent Citations (2)
Title |
---|
BULDUK IBRAHIM, TAKTAK FULYA: "Isolation and Characterization of Antitumor Alkaloid from Poppy Capsules ( Papaver somniferum )", JOURNAL OF CHEMISTRY, HINDAWI PUBLISHING CORPORATION, US, vol. 2013, 1 January 2013 (2013-01-01), US , pages 1 - 4, XP093081061, ISSN: 2090-9063, DOI: 10.1155/2013/493870 * |
CARLIN MICHELLE G., DEAN JOHN R., AMES JENNIFER M.: "Opium Alkaloids in Harvested and Thermally Processed Poppy Seeds", FRONTIERS IN CHEMISTRY, vol. 8, XP093081067, DOI: 10.3389/fchem.2020.00737 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102584769B (en) | Preparation method of natural VE with content of more than 99% | |
CN110835297A (en) | Method for extracting multiple active substances from waste liquid of ginkgo leaf extract production | |
WO2013191236A1 (en) | Composition for improving and/or treating central nervous system degenerative disease | |
JP2017520616A (en) | Extraction method of chlorogenic acid from Tochu leaves | |
KR20070119641A (en) | Isolation of galanthamine from biological material | |
CN107805270A (en) | A kind of ginsenoside Rh2Extracting method | |
JP5745499B2 (en) | Method for removing pesticides from ginkgo biloba extract and extract obtained by said method | |
WO2023136785A1 (en) | Noscapine extraction from poppy (opium) capsules | |
CN115260210B (en) | Cepharanthine crystal form and preparation method thereof | |
WO2007066926A1 (en) | A mass production method of brazilein from caesalpinia sappan l | |
TR2022015803T (en) | NOSCAPINE EXTRACTION FROM POPPY (OPIUM PLANT) CAPSULES | |
Jowett et al. | XXXVI.—The alkaloids of Xanthoxylum brachyacanthum | |
FI91639B (en) | Extraction of alkaloids | |
US1447400A (en) | Arthur stoll | |
KR20070074718A (en) | Theanine extraction process from green tea | |
CN107602642B (en) | Method for extracting and purifying trachelospermin from safflower seed | |
KR101153344B1 (en) | Kaempferitrin isolating and purifying method | |
US8394814B2 (en) | Method of purifying crude noscapine | |
EP1536787A2 (en) | Imidazole alkaloids from lepidium meyenii and methods of usage | |
CN105837645B (en) | The method that 3- methoxyl group ellagic acid -4-O- β-D-Glucose glycosides is extracted from Camellia Leaves | |
EP1446395B1 (en) | Method for the production of a phenolic substance from wood | |
SU878295A1 (en) | Method of obtaining hydrochloride desoxypeganine | |
MX2008012948A (en) | Narcotine purification process. | |
CN115010573B (en) | Method for reducing chromium content in lycopene crystal | |
US3147246A (en) | Obtention of an alkaloid from nuphar luteum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22920875 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |